Table 3.
Viability | ||
---|---|---|
MTT | HL7702 | 100.2% ± 0.4% |
HREpiC | 100.4% ± 0.7% | |
Hemolysis | ||
Hemolytic assay | 64 μg/mL | 0 |
128 μg/mL | 0 | |
256 μg/mL | 3.2% ± 1.7% | |
512 μg/mL | 19.5% ± 3.5% |
Viability | ||
---|---|---|
MTT | HL7702 | 100.2% ± 0.4% |
HREpiC | 100.4% ± 0.7% | |
Hemolysis | ||
Hemolytic assay | 64 μg/mL | 0 |
128 μg/mL | 0 | |
256 μg/mL | 3.2% ± 1.7% | |
512 μg/mL | 19.5% ± 3.5% |